Device Trial Radar · NCT01116024
ATS 3f Enable(tm) Aortic Bioprosthesis, Model 6000
Last checked: Nov 20, 2026Latest source record: Jun 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
173
Actual
Start
May 2006
Primary completion
Dec 2010
Study completion Aug 2012
Sponsor
- Lead sponsor
- Medtronic CardiovascularPublic (MDT)
- Sponsor type
- Industry
- First posted
- May 4, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, non-randomized, multi-center study designed to evaluate safety and effectiveness of the ATS 3f Enable Aortic Bioprosthesis in a patient population undergoing isolated aortic valve replacement with or without concomitant procedures. The Enable Aortic Valve is an equine pericardial stented bioprosthesis.
Conditions
- Heart Valve Diseases
Interventions
ATS 3f Enable Aortic Bioprosthesis Model 6000Device
Replacement Aortic Heart Valve
Primary outcomes
What the sponsor says the trial is designed to measure.
- Thromboembolism/ThrombosisTime frame: Five Years
- Hemorrhage/Bleeding-Anticoagulant/Antiaggregant (All and Major)Time frame: Five Years
- Paravalvular Leaks (All and Major)Time frame: Five Years
9 more outcomes with a free account
Locations
10 sites in 5 countries. Site status is shown where the registry gives one.
Medical University of Vienna
Vienna, Austria
Johann Wolfgang Goethe University
Frankfurt, Germany
University Medical Center Freiburg
Freiburg im Breisgau, Germany
7 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.